Hidetoshi Tahara

Last Updated :2024/05/15

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Pharmaceutical Sciences), Professor
E-mail
toshihiroshima-u.ac.jp
Other Contact Details
Kasumi 1-2-3, Minami-ku, Hiroshima, Japan
TEL : (+81)82-257-5290 FAX : (+81)82-257-5294
Self-introduction
My research fields are Telomere, microRNA and exosome in aging and cancer.

Basic Information

Major Professional Backgrounds

  • 2021/01/27, PURMX Therapeutics Inc., CEO
  • 2022/10/01, Hiroshima University, PSI GMP Education and Research Center, Director
  • 2012/04/01, 2020/03/31, MiRTeL.Co.Ltd., Chairman, Chief Executive Officer
  • 2008/04/01, Japanese Cancer Association (JCA), Councilor
  • 2008/04/01, Japanese Association for RNA interferences, President
  • 2021/04/01, Hiroshima University, Vice President (Academia-Government-Industry Collaboration)
  • 2019/04/01, 2021/03/31, Hiroshima University, Deputy Executive Director
  • 2019/04/01, Graduate School of Biomedical and Health Sciences, Hiroshima University, Professor
  • 2018/04/01, 2021/03/31, Graduate School of Biomedical & Health Sciences, Hiroshima University, Vice Dean
  • 2017/04/01, Graduate School of Biomedical & Health Sciences, Hiroshima University, Professor
  • 2017/04/01, 2019/03/31, Hiroshima University, The center of Biomarker and Drug Discovery, Head
  • 2016/04/01, School of Pharmaceutical Sciences, Hiroshima University, Program of Pharmaceutical Sciences, Head of Program
  • 2016/04/01, 2018/03/31, Institute of Biomedical & Health Sciences, Hiroshima University, Head, Basic Life Sciences, Head
  • 2014/04/01, 2006/03/31, Graduate School of Biomedical & Health Sciences, Hiroshima University, Department of Cellular and Molecular Biology, Professor
  • 2006/04/01, 2014/03/31, Graduate School of Biomedical Sciences, Department of Cellular and Molecular Biology, Division of Integrated Medical Science, Program for Biomedical Research, Professor
  • 2001/04/01, 2005/03/31, Faculty of Medicine, Hiroshima University, Institute of Pharmaceutical Sciences, Research Associate
  • 1998/01/01, 2000/01/31, National Institute of Health (NIH), National Institute of Environmental Health Sciences, Visiting Fellow
  • 1994/10/01, 2001/03/31, Faculty of Medicine, Hiroshima University, Institute of Pharmaceutical Sciences, Research Associate

Educational Backgrounds

  • Hiroshima University, Graduate School, Division of Medical Sciences, Japan, 1991/04, 1994/03
  • Tokyo University of Pharmacy and Life Science, Faculty of Pharmaceutical Science, Japan, 1985/04, 1989/03

Academic Degrees

  • Doctor of Philosophy in Pharmaceutical Science, Hiroshima University
  • Master of Pharmaceutical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Pharmaceutical Sciences : Program of Pharmaceutical Sciences : Pharmaceutical Sciences
  • [Bachelor Degree Program] School of Pharmaceutical Sciences : Program of Medicinal Sciences : Medicinal Sciences
  • [Master's Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Medicinal Sciences
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Medicinal Sciences
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Pharmaceutical Sciences

Research Fields

  • Biological Sciences;Oncology;Tumor biology
  • Biological Sciences;Oncology;Tumor diagnostics

Research Keywords

  • Telomerase
  • Immortalization
  • Telomere
  • Cellular senescence
  • microRNA
  • Exosome
  • Extracellular vesicles
  • Biomarker

Affiliated Academic Societies

  • Japanese Foundation for Cancer Research
  • International Society of Personalized Medicine
  • The Japanese Tissue Culture Association
  • Japanese Society of Anti-Aging Medicine
  • International Society of Practical Oncology, 2000, 2002
  • American Assciation for Cancer Research
  • Japanese RNAi association, 2008
  • Japanese Society of Extracellular Vesicles, 2014

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, 3Term, Biochemistry V
  2. 2024, Undergraduate Education, Intensive, Biochemistry V
  3. 2024, Undergraduate Education, 3Term, Introduction to Pharmaceutical Sciences
  4. 2024, Undergraduate Education, First Semester, Research Practice A
  5. 2024, Undergraduate Education, Second Semester, Research Practice B
  6. 2024, Undergraduate Education, First Semester, Practice of xenobiotics and molecular toxicology
  7. 2024, Undergraduate Education, 4Term, Biochemistry VI
  8. 2024, Undergraduate Education, Intensive, Biochemistry VI
  9. 2024, Undergraduate Education, 4Term, Cell Biology
  10. 2024, Undergraduate Education, 3Term, Japanese Pharmacopoeia
  11. 2024, Undergraduate Education, Second Semester, Experiments of Cellular and Molecular Biology
  12. 2024, Undergraduate Education, Year, Special laboratory Works in Pharmaceutical Sciences I
  13. 2024, Undergraduate Education, Year, Special laboratory Works in Pharmaceutical Sciences II
  14. 2024, Undergraduate Education, Second Semester, Special laboratory Works in Pharmaceutical Sciences III
  15. 2024, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy I
  16. 2024, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy II
  17. 2024, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy III
  18. 2024, Graduate Education (Master's Program) , 1Term, Seminar on Health Policy & Global Health
  19. 2024, Graduate Education (Doctoral Program) , 1Term, Methods in Biomedical Sciences B
  20. 2024, Graduate Education (Doctoral Program) , 3Term, Creation and Development of Biomedical Sciences
  21. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Cellular and Molecular Biology
  22. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Cellular and Molecular Biology
  23. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Cellular and Molecular Biology
  24. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Cellular and Molecular Biology
  25. 2024, Graduate Education (Master's Program) , First Semester, Lecture on Medicinal Science
  26. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Lecture on Medicinal Science
  27. 2024, Graduate Education (Master's Program) , First Semester, Seminar on Cell Regeneration
  28. 2024, Graduate Education (Master's Program) , Second Semester, Seminar on Cell Regeneration
  29. 2024, Graduate Education (Master's Program) , First Semester, Research on Cell Regeneration
  30. 2024, Graduate Education (Master's Program) , Second Semester, Research on Cell Regeneration
  31. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Cellular and Molecular Biology for Medicinal Sciences
  32. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Cellular and Molecular Biology for Medicinal Sciences
  33. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Cellular and Molecular Biology for Medicinal Sciences
  34. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Cellular and Molecular Biology for Medicinal Sciences

Research Activities

Academic Papers

  1. Immunocyte Derived Exosomes: Insight into the Potential Chemo- immunotherapeutic Nanocarrier Targeting the Tumor Microenvironment, ACS BIOMATERIALS SCIENCE & ENGINEERING, 9(1), 20-39, 20230109
  2. Plasma MicroRNAs as noninvasive diagnostic biomarkers in patients with Brugada syndrome, PLOS ONE, 17(5), 20220526
  3. Leukocyte Telomeric G-Tail Length Shortening Is Associated with Esophageal Cancer Recurrence, JOURNAL OF CLINICAL MEDICINE, 11(24), 202212
  4. Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(7), 202204
  5. Generation of disease-specific and CRISPR/Cas9-mediated gene-corrected iPS cells from a patient with adult progeria Werner syndrome, STEM CELL RESEARCH, 53, 202105
  6. Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan, SCIENTIFIC REPORTS, 12(1), 20220214
  7. Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines, ONCOLOGY, 70(6), 458-464, 2006
  8. Establishment of functional telomerase immortalized human hepatocytes and a hepatic stellate cell line for telomere-targeting anticancer drug development, CANCER SCIENCE, 101(7), 1678-1685, 201007
  9. Increased telomerase activity and hTERT expression in human salivary gland carcinomas, ONCOLOGY LETTERS, 2(5), 845-850, 2011
  10. Two unrelated patients with MRE1 1A mutations and Nijmegen breakage syndrome-like severe microcephaly, DNA REPAIR, 10(3), 314-321, 20110307
  11. miR-22 represses cancer progression by inducing cellular senescence, JOURNAL OF CELL BIOLOGY, 193(2), 409-424, 20110418
  12. Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair, NATURE GENETICS, 44(5), 593-+, 201205
  13. Human telomerase reverse transcriptase and glucose-regulated protein 78 increase the life span of articular chondrocytes and their repair potential, BMC MUSCULOSKELETAL DISORDERS, 13, 20120402
  14. Matrix Metalloproteinase-13 (MMP-13) Directly and Indirectly Promotes Tumor Angiogenesis, JOURNAL OF BIOLOGICAL CHEMISTRY, 287(46), 38716-38728, 20121109
  15. The role of exosomes and microRNAs in senescence and aging, ADVANCED DRUG DELIVERY REVIEWS, 65(3), 368-375, 201303
  16. Two Distinct Modes of ATR Activation Orchestrated by Rad17 and Nbs1, CELL REPORTS, 3(5), 1651-1662, 201305
  17. Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology, Pathol. Int., 49, 763-774, 19990401
  18. DNA-DNA Subtractive cDNA cloning using Oigo (dt)(30) -Latex and PCR-identification of cellular genes which are overexpressed in senescent human diploid fibroblasts., Anal Biochem, 214, 58-64, 19930401
  19. Preparation of subtractive cDNA library enriches in cDNAs which expressed at high level in cultured senescent human fibroblasts, Biochem. Biophys. Res. Commun., 199, 1108-1112, 19940401
  20. Telomerase activity in human liver tissues : Comparison between chronic liver disease and hepato cellular carcinoma., Cancer Research, 55, 2734-2736, 19950401
  21. Increase in expression level of interferon-inducible genes in senescent human diploid fibroblasts and in SV40-transformed human fibroblasts with extended lifespan, Oncogene, 10, 1125-1132, 19950401
  22. Inhibitors of cGMP-dependent protein kinase block seescence induced by inactivation of T antigen in SV40-fransformed immortal human fibroblasts, Oncogene, 11, 627-634, 19950401
  23. Telomerase activity in preneoplastic and neoplastic gastric and colovectal lesions, Clinical Cancer Research, 1, 1245-1251, 19950401
  24. Telomerase, 23, 247-256, 19960401
  25. A hVti1 homologue : Its expression depends on population doubling levels in both normal and SV40-transformed human fibroblasts., Biochem. Biophys. Res. Commun., 247, 70-74, 19980401
  26. Telomerase activation by the catalytic component gene TRT in human primary fibroblasts and hepatocellular carcinomas., Nature genetics, 18, 65-68, 19980401
  27. Alteration of telomeric repeat length in hepatocellular carcinoma is independent of telomerase activity., Int J Oncol, 11, 139-143, 19970401
  28. Immortakization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity., Differentiation, 62, 203-211, 19970401
  29. Telomerase activity in ovarian tumors., Cancer, 80, 1085-1092, 19970401
  30. Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinomas., Int J Cancer, 74, 141-147, 19970401
  31. Loss of amplified telomeric sequences associated with senescence in telomerasenegative SUSM-1 cells by introduction of human chromosome 7., Exp Cell Res, 235, 345-353, 19970401
  32. A rapid, useful and quantitative method to measure telomerase activity by hybridization protection assay(HPA)connected with telomeric repeat amplification protocol(TRAP)., J. Cancer Res. Oncol., 123, 337-344, 19970401
  33. Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinogenesis, Jpn.J.Cancer Res., 1187-1194, 19980401
  34. Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation., Surg. Neural, 267-274, 20000401
  35. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker., J Neurosurg, 618-625, 20000401
  36. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis, Cancer Letters, 149, 125-134, 20000401
  37. Inhibition of membrane Ca2+ ATPase of Saccharomyces cerevisiae by mating pheromone a factor in vitro, J. Gen. Microbiol.=, 137, 1-4, 19920401
  38. Expression of telomerase component genes in hepatocellular carcinomas., Eur. J. Cancer, 36, 496-502, 20000401
  39. Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues., Oncogene, 19, 3888-3893, 20000401
  40. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker., J Neurosurg, 93, 618-625, 20000401
  41. Growth inhibition of human glioma cells by transfection-induced P21 and its effects on telomerase activity., J. Neurooncol., 47, 39-46, 20000401
  42. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections., Oncogene, 18, 1561-1567, 19990401
  43. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach., Jpn.J.Cancer Res., 90, 589-595, 19990401
  44. Telomerase activity in central nervous system malignant lymphoma., Cancer, 86, 1050-1055, 19990401
  45. Telomerase activity in hybrids between telomerase-negative and telomerase-positive immortal human cells is repressed in the different complementation groups but not in the same complementation group of immortality., Mech. Ageing Dev., 110, 175-193, 19990401
  46. Quantitative re-evaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues., Mol. Carcinog., 26, 312-320, 19990401
  47. Telomerase activation by the catalytic component gene TRT in human primary fibroblasts and hepatocelluar carcinomas., Nature Genet., 18, 65-68, 19980401
  48. Extra-chromosomal telomere repeat DNA in telomerase-negative immortalized cell lines., Biochem. Biophys. Res. Commun., 247, 765-772, 19980401
  49. A hVti1 homologue: its expression depends on population doubling levels in both normal and SV40-transformed human fibroblasts., Biochem. Biophys. Res. Commun., 247, 70-74, 19980401
  50. A new method to detect and measure telomerase activity by transcription-mediated amplification (TMA) and hybridization protection assay (HPA)., Clinical Chem., 44, 2446-2452, 19980401
  51. In situ mRNA hybridization technique for analysis of human telomerase RNA in gastric precancerous and cancerous lesions., Jpn.J.Cancer Res., 89, 1099-1103, 19980401
  52. Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas., Jpn.J.Cancer Res., 89, 1187-1194, 19980401
  53. Alteration of telomeric repeat length in hepatocellular carcinoma is independent of telomerase activity., Int J Oncol, 11, 139-143, 19970401
  54. Telomerase activity in ovarian tumors., Cancer, 80, 1085-1092, 19970401
  55. Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinomas., Int J Cancer, 74, 141-147, 19970401
  56. Loss of amplified telomeric sequences associated with senescence in telomerase-negative SUSM-1 cells by introduction of human chromosome 7., Exp Cell Res, 235, 345-353, 19970401
  57. A rapid, useful and quantitative method to measure telomerase activity by hybridization protection assay (HPA) connected with telomeric repeat amplification protocol (TRAP)., J Cancer Res Clin Oncol, 123, 337-344, 19970401
  58. Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity., Diffrentiation, 52, 203-211, 19970401
  59. Telomerase in hepatocellular carcinogenesis., Human Cell, 9, 283-286, 19960401
  60. Telomerase activity in normal human epithelial cells., Oncogene, 13, 433-439, 19960401
  61. Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspirates., Int J Cancer, 69, 301-306, 19960401
  62. Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinomas., Cancer Res., 55, 2734-2736, 19950401
  63. Increase in expression level of p21sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts., Oncogene, 10, 835-840, 19950401
  64. Increase in expression levels of interferon-inducible genes in senescent human diploid fibroblasts and in SV40-transformed human fibroblasts with extended lifespan., Oncogene, 11, 1125-1132, 19950401
  65. Inhibitors of cGMP-dependent protein kinase block senescence induced by inactivation of T antigen in SV40-transformed immortal human fibroblasts., Oncogene, 11, 627-634, 19950401
  66. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3., Jpn.J.Cancer Res., 86, 899-904, 19950401
  67. Telomerase activity in precancerous and cancerous lesions of gastric and colorectal tissues., Clinical Cancer Res., 1, 1245-1251, 19950401
  68. Preparation of a substractive cDNA library enriched in cDNAs which expressed at a high level in cultured senescent human fibroblasts., Biochem. Biophys. Res. Commun., 199, 1108-1112, 19940401
  69. DNA-DNA subtractive cDNA cloning using oligo(dT)30-latex and PCR: Identification of cellular genes which are overexpressed in senescent human diploid fibroblasts., Anal Biochem, 214, 58-64, 19930401
  70. Telomerase activity in various precancerous and cancer tissues, The Proceedings of 87th Annual Meeting of the American Association for Cancer Reserch, 19960401
  71. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas, INTERNATIONAL JOURNAL OF ONCOLOGY, 19(3), 507-512, 20010401
  72. Distinct pattern of p53 phosphorylation in human tumors, Oncogene, 20(26), 3341-3347, 20010401
  73. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis, Cancer Letters, 149(2001/01/02), 125-134, 20000401
  74. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker, Journal of Neurosurgery, 93(4), 618-625, 20000401
  75. Growth inhibition of human glioma cells by transfection-induced P21 and its effects on telomerase activity, Journal of Neuro-Oncology, 47(1), 39-46, 20000401
  76. Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation, Surgical Neurology, 53(3), 267-274, 20000401
  77. Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues, Oncogene, 19(34), 3888-3893, 20000401
  78. Immortalization of mammary cells from estrogen receptor alpha knock-out and wild-type mice, In Vitro Cellular of Developmental Biology, 36(10), 620-624, 20000401
  79. Expression of telomerase component genes in hepatocellular carcinomas, European Journal of Cancer, 36(4), 496-502, 20000401
  80. Cloning of a human hepatocyte growth factor/scatter factor transcription variant from a gastric cancer cell line HSC-39, INTERNATIONAL JOURNAL OF ONCOLOGY, 16(1), 105-108, 20000401
  81. Telomerase activity in central nervous system malignant lymphoma, Cancer, 86(6), 1050-1055, 19990401
  82. Telomerase activity in hybrids between telomerase-negative and telomerase-positive immortal human cells is repressed in the different complementation groups but not in the same complementation group of immortality, Mechanisms of Ageing and Development, 110(3), 175-193, 19990401
  83. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines, Biochemical and Biophysical Research Communications, 255(3), 753-758, 19990401
  84. Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues, Molecular Carcinogenesis, 26(4), 312-320, 19990401
  85. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections, Oncogene, 18(8), 1561-1567, 19990401
  86. Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology, Pathology International, 49(9), 763-774, 19990401
  87. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach, Japanese Journal of Cancer Research, 90(6), 589-595, 19990401
  88. Telomerase activity in lesions of the thyroid: Application to diagnosis of clinical samples including fine-needle aspirates, Clinical Cancer Research, 4(8), 1965-1970, 19980401
  89. New method to measure telomerase activity by transcription-mediated amplification and hybridization protection assay, Clinical Chemistry, 44(12), 2446-2452, 19980401
  90. In situ mRNA hybridization technique for analysis of human telomerase RNA in gastric precancerous and cancerous lesions, Japanese Journal of Cancer Research, 89(11), 1187-1194, 19980401
  91. A hVti1 homologue: Its expression depends on population doubling levels in both normal and SV40-transformed human fibroblasts, Biochemical and Biophysical Research Communications, 247(1), 70-74, 19980401
  92. Diagnostic value of telomerase activity in gynecologic malignancies, International Journal of Gynecological Cancer, 8(6), 481-488, 19980401
  93. ★, Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas, Nature genetics, 18(1), 65-68, 19980401
  94. A quantitative method to measure telomerase activity by hybridization protectin assay (HPA) connected with TRAP for the diagnosis of hepatocellular carcinoma (HCC)., Gastroenterology, 114(4), A1351-A1351, 19980401
  95. Extra-chromosome telomere repeat DNA in telomerase-negative immortalized cell lines, Biochemical and Biophysical Research Communications, 247(3), 765-772, 19980401
  96. Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas, Japanese Journal of Cancer Research, 89(11), 1099-1103, 19980401
  97. A rapid, useful and quantitative method to measure telomerase activity by hybridization protection assay connected with a telomeric repeat amplification protocol, Journal of Cancer Research and Clinical Oncology, 123(6), 337-344, 19970401
  98. Telomerase activity in premalignant and malignant lesions of human oral mucosal, 6(6), 413-420, 19970401
  99. Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity, Differentiation, 62(4), 203-211, 19970401
  100. Expression of human telomerase RNA is an early event of stomach carcinogenesis, Japanese Journal of Cancer Research, 88(2), 103-107, 19970401
  101. Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27(Kip1) in a human gastric carcinoma cell line, 8(1), 47-52, 19970401
  102. Telomerase activity in ovarian tumors, Cancer, 80(6), 1085-1092, 19970401
  103. Decrease in amplified telomeric sequences and induction of senescence markers by introduction of human chromosome 7 or its segments in SUSM-1, Experimental Cell Research, 235(2), 345-353, 19970401
  104. Alteration of telomeric repeat length in hepatocellular carcinoma is independent of telomerase activity, INTERNATIONAL JOURNAL OF ONCOLOGY, 11(1), 139-143, 19970401
  105. Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinoma, International journal of cancer, 74(2), 141-147, 19970401
  106. Modified trap assay for the diagnosis of small differentiated hepatocellular carcinoma (HCC)., Gastroenterology, 112(4), A1344-A1344, 19970401
  107. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine, Cancer, 79(2), 362-369, 19970401
  108. Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells, Jpn.J.Cancer Res., 87(4), 377-384, 19960401
  109. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines, Jpn.J.Cancer Res., 87(8), 824-830, 19960401
  110. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence, Mol. Cell. Biol., 16(3), 859-867, 19960401
  111. Telomerase in hepatocellular carcinogenesis, Hum Cell, 9(4), 283-286, 19960401
  112. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates, Int J Cancer, 69(4), 301-306, 19960401
  113. Molecular biological observations in gastric cancer, Semin Oncol, 23(3), 307-315, 19960401
  114. Telomerase activity in normal human epithelial cells, Oncogene, 13(2), 433-439, 19960401
  115. Inhibitors of cGMP-dependent protein kinase block senescence induced by inactivation of T antigen in SV40-transformed immortal human fibroblasts, Oncogene, 11(4), 627-634, 19950401
  116. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3, Jpn.J.Cancer Res., 86(10), 899-904, 19950401
  117. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions, Clin. Cancer Res., 1(11), 1245-1251, 19950401
  118. Increase in expression levels of interferon-inducible genes in senescent human diploid fibroblasts and in SV40-transformed human fibroblasts with extended lifespan, Oncogene, 11(6), 1125-1132, 19950401
  119. ★, Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas, Cancer Res., 55(13), 2734-2736, 19950401
  120. ★, Increase in expression level of p21sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts, Oncogene, 10(5), 835-840, 19950401
  121. Preparation of a subtractive cDNA library enriched in cDNAs which expressed at a high level in cultured senescent human fibroblasts, Biochem. Biophys. Res. Commun., 199(3), 1108-1112, 19940401
  122. DNA-DNA subtractive cDNA cloning using oligo(dT)30-Latex and PCR: identification of cellular genes which are overexpressed in senescent human diploid fibroblasts, Anal Biochem, 214(1), 58-64, 19930401
  123. Genetic Status and Expression of the Cyclin-dependent Kinase Inhibitors in Human Gastric Carcinoma cell Lines, Jpn.J.Cancer Res., 87, 824-830, 19960101
  124. Expression of CDK inhibitor p21 and CDK2 in human colorectal carcinoma cell lines: relation with p53 status, Recent Advances in Gastroenterological Carcinogenesis., 749-753
  125. Involvement of telomere shortening and telomerase in cell aging and immortalization (M. Goto Ed.),, 147-163, 20010401
  126. Telomere and telomerase in Gastrointestinal cancers, 245-259., 19970401
  127. Expression of MRE11 complex (MRE11, RAD50, NBS1) and hRap1 and its relation with telomere regulation, telomerase activity in human gastric carcinomas., Pathobiology, 69, 219-224, 20010401
  128. Expression and distribution of human telomerqase catalytic component, hTERT, in human breast tissues., Anticancer Research, 22, 4101-4108, 20020401
  129. In vitro establishment of tumorigenic human B-lymphoblastoid cell lines transformd by Epstein-Barr virus., DNA and Cell Biology, 20030401
  130. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus., Cancer Research, 64, 3361-3364, 20040401
  131. WRN gene and other genetic factors affecting immortalization of human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Genet., Cytogenet., 152, 95-100, 20040401
  132. Establishment of lifespan-extended human astrocytes with normal phenotypes by introduction of telomerase gene., Tissue Cult. Res. Commun., 23, 59-69, 20040401
  133. Telomeres and telomerase in hepatocellular carcinoma., Recent Res. Devel. Cancer, 6, 191-210, 20040401
  134. Terminal telomere repeats are actually short in telomerase-negative immortal human cells., Biol. Pharm. Bull., 27, 1932-1938, 20040401
  135. G1P3, An interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial mediated apoptosis in gastric cancer cell line TMK-1., Cancer Immunol. Immunoth., 54(8), 729-740, 20050401
  136. Establishment of cementoblast cell lines from rat cementum lining cells by transfection with temperature-sensitive simian virus-40 T-antigen gene., BONE, 37, 220-226, 20050401
  137. Microgravity potentiates stem cell proliferation while sustaining the capability of differentiation., Stem Cells Dev, 15(6), 921-929, 20061201
  138. Immortalization and characterization of human dental pulp cells with odontoblastic differentiation., Archives of Oral Biology, 52(8), 727-731, 20070801
  139. Characterization of established cementoblast-like cell lines from human cementum lining cells in vitro and in vivo., Bone, 39(5), 1035-1042, 20061101
  140. Telomerase activation induces elongation of the telomeric single-stranded overhang, but does not prevent chromosome aberrations in human vascular endothelial cells., Biochemical and biophysical research communications, 926-932, 20070223
  141. Terminal telomere repeats are actually short in telomerase-negative immortal human cells., Biological & Pharmaceutical Bulletin, 27, 1932-1938, 20041201
  142. ★, G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells., Oncogene, 25(13), 1955-1966, 20060323
  143. Establishment of immortalized clonal cells derived from periodontal ligament cells by induction of the hTERT gene., Journal of Oral Science, 47(4), 177-184, 20051201
  144. ★, G-tail telomere HPA: simple measurement of human single-stranded telomeric overhangs, Nature Methods, 2(11), 829-831, 20051101
  145. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres., Cell, 126(1), 49-62, 20060714
  146. POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination., European Molecular Biology Organization, 25(21), 5180-5190, 20061101
  147. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence., Nature Cell Biology, 8(11), 1291-1297, 20061101
  148. Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome., American Journal of Medical Genetics, 140(4), 358-367, 20060215
  149. Quantitative proteomic analysis of human breast epithelial cells with differential telomere length, BBRC, 356(4), 942-947, 20070318
  150. Telomerase activation induces elongation of the telomeric single-stranded overhang, but does not prevent chromosome aberrations in human vascular endothelial cells., BBRC, 353(4), 926-932, 20070223
  151. Immortalization and characterization of pleomorphic adenoma cells by transfection with the hTERT gene., International Journal Of Oncology, 31(2), 339-344, 20070801
  152. IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3., Biochem. Biophys. Res. Commun., 337(1), 201-208, 20051111
  153. Two unrelated patients with MRE11A mutations and Nijmegen breakage syndrome-like severe microcephaly., DNA Repair (Amst), 20110301
  154. Telomere G-Overhang Length Measurement Method 2: G-Tail Telomere HPA, Methods in Molecular Biology, 735, 55-61, 20110301
  155. Introduction of a Single Transporter Gene ABCA3 Directs RLE–6TN to More Type II–like Alveolar Epithelial Cells, MEMBRANE, 38(5), 246-253, 20130801
  156. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker, JOURNAL OF NEUROSURGERY, 93(4), 618-625, 200010
  157. Distinct pattern of p53 phosphorylation in human tumors, ONCOGENE, 20(26), 3341-3347, 20010607
  158. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas, INTERNATIONAL JOURNAL OF ONCOLOGY, 19(3), 507-512, 200109
  159. Expression of MRE11 complex (MRE11, RAD50, NBS1) and hRap1 and its relation with telomere regulation, telomerase activity in human gastric carcinomas, PATHOBIOLOGY, 69(4), 219-224, 2001
  160. Association of p16(INK4a) and pRb inactivation with immortalization of human cells, CARCINOGENESIS, 23(12), 2111-2117, 200212
  161. Expression and distribution of human telomerase catalytic component, hTERT, in human breast tissues, ANTICANCER RESEARCH, 22(6C), 4101-4107, 2002
  162. In vitro establishment of tumorigenic human B-lymphoblastoid cell lines transformed by Epstein-Barr virus, DNA AND CELL BIOLOGY, 22(11), 727-735, 200311
  163. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus, CANCER RESEARCH, 64(10), 3361-3364, 20040515
  164. WRN gene and other genetic factors affecting immortalization of human B-lymphoblastoid cell lines transformed by Epstein-Barr virus, CANCER GENETICS AND CYTOGENETICS, 152(2), 95-100, 20040715
  165. Terminal telomere repeats are actually short in telomerase-negative immortal human cells, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 27(12), 1932-1938, 200412
  166. G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell, CANCER IMMUNOLOGY IMMUNOTHERAPY, 54(8), 729-740, 200508
  167. IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 337(1), 201-208, 20051111
  168. G-taff teLomere HPA: simple measurement of human single-stranded telomeric overhangs, NATURE METHODS, 2(11), 829-831, 200511
  169. Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome, AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 140A(4), 358-367, 20060215
  170. G-quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3 ' telomeric overhang in cancer cells, ONCOGENE, 25(13), 1955-1966, 20060323
  171. Telomere and telomerase in age related diseases, SEIKAGAKU, 78(3), 230-241, 200603
  172. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres, CELL, 126(1), 49-62, 20060714
  173. Mitogenic signalling and the p16(INK4a)-Rb pathway cooperate to enforce irreversible cellular senescence, NATURE CELL BIOLOGY, 8(11), 1291-U63, 200611
  174. Telomerase activation induces elongation of the telomeric single-stranded overhang, but does not prevent chromosome aberrations in human vascular endothelial cells, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 353(4), 926-932, 20070223
  175. Characterization of established cementoblast-like cell lines from human cementum-lining cells in vitro and in vivo, BONE, 39(5), 1035-1042, 200611
  176. POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination, EMBO JOURNAL, 25(21), 5180-5190, 20061101
  177. Quantitative proteomic analysis of human breast epithelial cells with differential telomere length, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 356(4), 942-947, 20070518
  178. Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation, EXPERIMENTAL CELL RESEARCH, 314(5), 1115-1124, 20080310
  179. Role of menin in the regulation of telomerase activity in normal and cancer cells, INTERNATIONAL JOURNAL OF ONCOLOGY, 33(2), 333-340, 200808
  180. A Chiral Wedge Molecule Inhibits Telomerase Activity, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 132(11), 3778-3782, 20100324
  181. Cooperation of DNA-PKcs and WRN helicase in the maintenance of telomeric D-loops, AGING-US, 2(5), 274-284, 201005
  182. Pin1 Associates with and Induces Translocation of CRTC2 to the Cytosol, Thereby Suppressing cAMP-responsive Element Transcriptional Activity, JOURNAL OF BIOLOGICAL CHEMISTRY, 285(43), 33018-33027, 20101022
  183. MicroRNAs in Cancer: The 22nd Hiroshima Cancer Seminar/The 4th Japanese Association for RNA Interference Joint International Symposium, 30 August 2012, Grand Prince Hotel Hiroshima, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 43(5), 579-582, 201305
  184. Generation of Human Induced Pluripotent Stem (Ips) Cells in Serum- and Feeder-Free Defined Culture and TGF-B1 Regulation of Pluripotency, PLOS ONE, 9(1), 20140129
  185. CBP-93872 Inhibits NBS1-Mediated ATR Activation, Abrogating Maintenance of the DNA Double-Strand Break-Specific G(2) Checkpoint, CANCER RESEARCH, 74(14), 3880-3889, 20140715
  186. TERT attenuated ER stress-induced cell death, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 447(2), 378-382, 20140502
  187. DSE-FRET: A new anticancer drug screening assay for DNA binding proteins, CANCER SCIENCE, 105(7), 870-874, 201407
  188. Decreased Amyloid-beta Pathologies by Intracerebral Loading of Glycosphingolipid-enriched Exosomes in Alzheimer Model Mice, JOURNAL OF BIOLOGICAL CHEMISTRY, 289(35), 24488-24498, 20140829
  189. Infection with Porphyromonas gingivalis Exacerbates Endothelial Injury in Obese Mice, PLOS ONE, 9(10), 20141021
  190. A potential function for neuronal exosomes: Sequestering intracerebral amyloid-beta peptide, FEBS LETTERS, 589(1), 84-88, 20150102
  191. EVpedia: a community web portal for extracellular vesicles research, BIOINFORMATICS, 31(6), 933-939, 20150515
  192. Reprogramming Suppresses Premature Senescence Phenotypes of Werner Syndrome Cells and Maintains Chromosomal Stability over Long-Term Culture, PLOS ONE, 9(11), 20141112
  193. Telomeric G-Tail Length and Hospitalization for Cardiovascular Events in Hemodialysis Patients, CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 9(12), 2117-2122, 201408
  194. Mutations in the Gene Encoding the E2 Conjugating Enzyme UBE2T Cause Fanconi Anemia, AMERICAN JOURNAL OF HUMAN GENETICS, 96(6), 1001-1007, 20150604
  195. Telomere G-tail Length is a Promising Biomarker Related to White Matter Lesions and Endothelial Dysfunction in Patients With Cardiovascular Risk: A Cross-sectional Study, EBIOMEDICINE, 2(8), 960-967, 201508
  196. microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer, ONCOTARGET, 7(7), 8223-8239, 20160216
  197. Inhibition of telomerase causes vulnerability to endoplasmic reticulum stress-induced neuronal cell death, NEUROSCIENCE LETTERS, 629, 241-244, 20160826
  198. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA - an ISEV position paper, JOURNAL OF EXTRACELLULAR VESICLES, 6, 2017
  199. Werner Syndrome-specific induced pluripotent stem cells: recovery of telomere function by reprogramming, FRONTIERS IN GENETICS, 6, 20150129
  200. Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles, STEM CELLS TRANSLATIONAL MEDICINE, 6(8), 201708
  201. Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations, STEM CELLS, 36(3), 434-445, 201803
  202. Levels of tight junction protein CLDND1 are regulated by microRNA-124 in the cerebellum of stroke-prone spontaneously hypertensive rats, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 498(4), 817-823, 20180415
  203. TERT enhances the survival rate of human fibroblasts under endoplasmic reticulum, Golgi apparatus, and lysosomal stresses, BIOTECHNOLOGY LETTERS, 40(6), 915-922, 201806
  204. Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017, JOURNAL OF EXTRACELLULAR VESICLES, 7(1), 20180517
  205. Chromosome 4q25 Variant rs6817105 Bring Sinus Node Dysfunction and Left Atrial Enlargement, SCIENTIFIC REPORTS, 8, 20181001
  206. Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells, SCIENTIFIC REPORTS, 8, 20181004
  207. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines, JOURNAL OF EXTRACELLULAR VESICLES, 8(1), 20190101
  208. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines, JOURNAL OF EXTRACELLULAR VESICLES, 7(1), 20181123
  209. Influence of donor liver telomere and G-tail on clinical outcome after living donor liver transplantation, PLOS ONE, 14(3), 20190307
  210. Targeting DNA binding proteins for cancer therapy, CANCER SCIENCE, 111(4), 1058-1064, 202004
  211. Diagnostic performance of peripheral leukocyte telomere G-tail length for detecting breast cancer, CANCER SCIENCE, 111(5), 1856-1861, 202005
  212. Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma, PLOS ONE, 15(4), 20200406
  213. Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles, CANCER SCIENCE, 111(6), 2104-2115, 202006
  214. Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors, SCIENTIFIC REPORTS, 10(1), 20200831
  215. Identification of a Selective RelA Inhibitor Based on DSE-FRET Screening Methods, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(23), 202012
  216. Molecular characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima, Japan, PLOS ONE, 16(2), 20210205
  217. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA, JOURNAL OF BIOLOGICAL CHEMISTRY, 297(1), 202107
  218. The power of imaging to understand extracellular vesicle biology in vivo, NATURE METHODS, 18(9), 1013-1026, 202109
  219. Peptide-based electrochemical sensor with nanogold enhancement for detecting rheumatoid arthritis, TALANTA, 236, 20220101
  220. Continuous polymerase chain reaction microfluidics integrated with a gold-capped nanoslit sensing chip for Epstein-Barr virus detection, BIOSENSORS & BIOELECTRONICS, 195, 20220101
  221. Nanoplasmonic Structure of a Polycarbonate Substrate Integrated with Parallel Microchannels for Label-Free Multiplex Detection, POLYMERS, 13(19), 202110
  222. A nanofluidic preconcentrator integrated with an aluminum-based nanoplasmonic sensor for Epstein-Barr virus detection, SENSORS AND ACTUATORS B-CHEMICAL, 355, 20220315
  223. Development of a water refractive index-matched microneedle integrated into a light sheet microscopy system for continuous embryonic cell imaging, LAB ON A CHIP, 22(3), 584-591, 20220201

Publications such as books

  1. 2001, Involvement of telomere and telomerase in aging and cell immortalization , Cann Monograph on Cancer Research No.49, 2001
  2. 1996, Telomerase activity and genetic changes in human colorectal cancers , New strategies for Treatment of Hereditary colovectal cancers, 1996
  3. 1996, Telomerase activity in gastrointestinal cancers , 1996

Invited Lecture, Oral Presentation, Poster Presentation

  1. Co-Create the Next Value with Bio Ecosystems in Japan, BIO-EUROPE2022, 2022/10/24, Without Invitation, Japanese
  2. Investigator-initiated clinical trial of MIRX002, an anti-tumor nucleic acid medicine for malignant pleural mesothelioma, MOPM2022 conference, 2022/11/19, With Invitation, Japanese
  3. First-in-human investigator-initiated clinical trial of a nucleic acid medicine for malignant pleural mesothelioma, 2022/09/07, With Invitation, Japanese
  4. COVID-19 research at Hiroshima University, Hidetoshi Tahara, 2020/10/08, With Invitation, English, UNIVERSITY OF GOTHENBURG International Centre
  5. Identification of circulating small RNAs as novel biomarkers for breast cancer detection, Yumiko Koi, Yuki Yamamoto, Ryou-u Takahashi, Morihito Okada, Hidetoshi Tahara, 2020/10/03, Without Invitation, Japanese
  6. PRPF19 exerts a functional role in p53-dependent cellular senescence via regulating MDM4 splicing, Kimiyoshi Yano, Shisei Kan, Hiroki Sakagami, Ryou-u Takahashi,Hidetoshi Tahara, 2020/10/03, Without Invitation, Japanese
  7. A treatment of malignant pleural mesothelioma using a novel senescence-associated miRNA miR-3140-3p, Yuki Yamamoto, Kimiyoshi Yano, Noriaki Matsuda, Ryou-u Takahashi, Morihito Okada, Hidetoshi Tahara, 2020/10/03, Without Invitation, Japanese
  8. Pre-mRNA processing factor 19 (PRPF19) as a key regulator inaging and cancer, 2020/10/03, With Invitation, Japanese
  9. The potential for microRNA therapeutics: Pre-clinical study of locally administered miRNA for malignant mesothelioma, 2020/10/03, With Invitation, Japanese
  10. Non-clinical study of locally administered microRNA nucleic acid medicine for malignant pleural mesothelioma, Hidetoshi Tahara, 2019/08/29, With Invitation, Japanese
  11. Circulating small RNAs in the serum as novel biomarkers for breast cancer detection, Yumiko Koi,Yasuhiro Tsutani, Yukie Nishiyama, Shinsuke Sasada, Tomoyuki Akita, NorioMasumoto, Takayuki Kadoya, Ryou-u Takahashi, Junko Tanaka, Morihito Okada, Hidetoshi Tahara, 2019/08/29, Without Invitation, Japanese
  12. Identification of PRPF19 as a novel target gene of senescence-associated microRNA; miR-27b-3p, Kimiyoshi Yano, Shisei Kan, Hiroki Sakagami, Ryou-u Takahashi and Hidetoshi Tahara, 2019/08/29, Without Invitation, Japanese
  13. The development of a novel nucleic acid drug against malignant pleural mesothelioma, Ayaka Nishiura, Yuki Yamamoto, Kimiyoshi Yano, Saori Fukunaga, Issei Shibuya, Ryou-u,Takahashi, Hidetoshi Tahara, 2019/08/28, Without Invitation, Japanese
  14. Senescent cells-derived extracellular vesicles repress tumour growth by transferring miR-127-3p and miR-134-5p., Megumi Okada,Kimiyoshi Yano,Shigeyuki Teranishi,Mariko Ikuo,Hidetoshi Tahara, ISEV2019, 2019/04/27, Without Invitation, English
  15. The factor affecting to the accuracy of extracellular small non-coding RNA biomarkers, Yukie Nishiyama,Yumiko Koi,Genki Nishimura, Eri Kojima,Morihito Okada,Hidetosi Tahara, ISEV2019, 2019/04/27, Without Invitation, English
  16. Isolation and characterization of bovine milk-derived Evs., Saori Fukunaga,Yuki Yamamoto,Hidetoshi Tahara, ISEV2019, 2019/04/26, Without Invitation, English
  17. BMP2 dependent osteoblast defferentiation is suppressed by multiplemyeloma-derived extracellular vesicles, Mariko Ikuo, ISEV2019, 2019/04/26, Without Invitation, English
  18. Characterization of extracellular vesicles (EVs) derived exRNA in cancer using NGS, Hidetoshi Tahara, qPCR dPCR & NGS 2019, 2019/03/18, With Invitation, English, Weihenstephan,Germany
  19. Telomere and microRNA in aging, 2018/10/10, With Invitation, Japanese
  20. MicroRNAs,isomiRs and tRFs are promising biomarkers as liquid biopsy for breast cancer detection., 2018/09/27, Without Invitation, Japanese
  21. A novel mechanism of p53-dependent cellular senescence by silencing of PRPF19, 2018/08/31, Without Invitation, Japanese
  22. Novel Senescence-Associated microRNA suppress malignant pleural mesothelioma, 2018/08/31, Without Invitation, Japanese
  23. A novel mechanism of p53-dependent cellular senescence by silencing of PRPF19, 2018/08/30, Without Invitation, Japanese
  24. Exploration of hemolysis-associated small non-coding RNA by Next Generation Sequence, 2018/08/30, Without Invitation, Japanese
  25. Novel Senescence-Associated microRNA suppress malignant pleural mesothelioma, 2018/08/29, Without Invitation, Japanese
  26. The relationship between human aging and advanced glycation end products of extracellular vesicles in serum., 2018/08/29, Without Invitation, Japanese
  27. Age-related expression change of circulating small non-coding RNAs, 2018/08/29, Without Invitation, Japanese
  28. Extracelluar vesicles derived from senescencet cells repress tumour growth via miRNAs, Mariko Ikuo,Megumi Okada, Shigeyuki Teranishi,Masaki Kinehara,Akira Shimamoto,Hidetoshi Tahara, ISEV2018, 2018/05/05, Without Invitation, English, Barcelona(Reino de España)
  29. Extracelluler small non-coding RNAs as promising biomarkers for early cancer detection, Yukie Nishiyama,Yumiko Koi,Genki Nishimura,Eri Kojima,Morihito Okada,Hidetoshi Tahara, ISEV2018, 2018/05/05, Without Invitation, English, Barcelona(Reino de España)
  30. Development of novel TRF2 inhibitor, Yoshitomo Shiroma,Go Fujita, Hidetoshi Tahara, EMBO Workshop, 2018/05/02, Without Invitation, English, Troia(Portugal)
  31. Application of exRNA and Circulating RNA for Early Detection of Cancer, Hidetoshi Tahara, Extracellular Vesicles as Biomarkers of Disease, 2017/12/13, Without Invitation, English
  32. Senescence cell - derived extracellular vesicles repress tumor growth, 2017/12/09, Without Invitation, Japanese
  33. Senescence cell - derived extracellular vesicles repress tumor growth, 2017/12/08, Without Invitation, Japanese
  34. Small non - coding RNA as biomarker promising early detection of pancreatic cancer, 2017/12/07, Without Invitation, Japanese
  35. Development of inhibitor of telomere binding protein using DSE-FRET assay, 2017/12/07, Without Invitation, Japanese
  36. Discovery and function analysis of RelA-DNA binding inhibitor using NF-kB DSE-FRET assay, 2017/12/07, Without Invitation, Japanese
  37. The association between glycation of sueface proteins on extracellular vesicles in serum and aging, 2017/12/06, Without Invitation, Japanese
  38. Senescence-associated microRNAs suppress malignant pleural mesothelioma cells, 2017/12/06, Without Invitation, Japanese
  39. Nucleic acid medicine based senescence-associated microRNAs for cancer therapy, 2017/12/06, Without Invitation, Japanese
  40. Mechanism of p53 activation via silenceing of PRPF19 in cellular senescence, 2017/12/06, Without Invitation, Japanese
  41. Validation of circulating microRNA using NGS, 2017/11/01, With Invitation, English
  42. "Cancer dormancy induced by Dox-inducible cancer stem cell model is maintained by BMP signaling", 2017/09/30, Without Invitation, Japanese
  43. "Novel senescence-associated microRNAs inhibit proliferation of intractable cancer cells", 2017/09/30, Without Invitation, Japanese
  44. The effect of TRF2 inhibitors in cancer cells, 2017/09/30, Without Invitation, Japanese
  45. PRPF19 is a novel potent molecular target for tumor suppression, 2017/09/30, Without Invitation, Japanese
  46. Senescence-associated microRNAs act as tumor suppressor hor both cancer stem cells and anti-cancer drug cancer cells, Hidetoshi Tahara, 2nd Global Insight Conference on Breast Cancer, 2017/09/05, Without Invitation, English, Rome
  47. Identification of serum preparation method that can get consistent circulating ncRNA profile., 2017/08/31, Without Invitation, Japanese
  48. Next-Generation Sequence analysis of exosomal small RNA isolated from cell culture media., 2017/08/30, Without Invitation, English
  49. miRNA in aging and cancer, 2017/08/28, With Invitation, English
  50. "An in vitro model for cancer stem cell dormancy and recurrence using tetinducible reprogramming system", 2017/07/01, With Invitation, Japanese
  51. Screening of senescence-inducible microRNAs for cancer therapy, 2017/07/01, Without Invitation, Japanese
  52. MicroRNA and exosome in Aging, Hidetoshi Tahara, 2017/06/15, With Invitation, English
  53. Extracellular RNA is promising biomarker for eary detection of cancers, Hidetoshi Tahara, Yukie Nishiyama,Yumiko Koui,Yuki Yamamoto,Genki Nishimura,Masaki Kinehara,Akira Shimamoto,Morito Okada,Hidetoshi Tahara, ISEV2017, 2017/05/19, Without Invitation, English, Toronto,Canada
  54. Circulating microRNAs as novel promising biomarkers for early detection of Tongue Cancer, Hidetoshi Tahara, ESMO ASIA, 2017/01/16, Without Invitation, Japanese, シンガポール
  55. Screening of senescence-associated microRNAs having anti- proliferative effect in human cancer cells, 2016/10/08, Without Invitation, Japanese
  56. Biogenesisandbiologicalactivitiesofexosomesderivedfrom replicative senescent fibroblast cells, 2016/10/08, Without Invitation, Japanese
  57. Application of senescence-inducible microRNAs for cancer therapy, 2016/10/06, With Invitation, Japanese
  58. Induction of cancer stem cell dormancy and recurrence by Dox-inducible secondary reprogramming system, 2016/10/06, Without Invitation, Japanese
  59. The potential for applying PRPF19 siRNA to anti-cancer therapeutics, 2016/09/14, Without Invitation, Japanese
  60. The potential for applying PRPF19 siRNA to anti-cancer therapeutics, 2016/09/01, Without Invitation, Japanese
  61. Functional analysis of exosomal miRNA derived from senescent cells, 2016/08/31, Without Invitation, Japanese
  62. p16-dependent induction of cell death by senescence-inducible microRNA in pancreatic cancer cells., 2016/08/31, Without Invitation, Japanese
  63. Nucleic Acid Therapeutics targeting microRNAs, 2016/07/30, With Invitation, Japanese
  64. The Significant Function Of EVs In Aging And Cancer, Hidetoshi Tahara, Extracellular Vesicles 2016, 2016/07/12, Without Invitation, English, Cambridge, UK
  65. Apoptotic Effect of Senescence-inducible microRNAs on Human Cancer Cell Lines, Masaki Kinehara,Yuki Yamamoto,Saori Fukunaga,Akira Shimamoto,Hidetoshi Tahara, 2016/06/24, Without Invitation, Japanese
  66. Inhibition of cancer cell growth by senescence-inducible miRNA, 2016/05/25, Without Invitation, Japanese
  67. "Non-coding RNAs Senescence-associated EVs from fibroblasts act as tumor suppressor at the tumor microenvironment.", Hidetoshi Tahara, 2016/02/18, Without Invitation, English, other
  68. Depletion of PRPF19 regulates cell fate between cellular senescence and cell death, 2015/12/03, Without Invitation, Japanese, other
  69. Histone variant H3.3 depletion induces cellular senescence in human diploid fibroblasts, 2015/12/02, Without Invitation, Japanese, other
  70. FunctionalanalysisofmiR-486inpancreaticcancer, 2015/10/10, Without Invitation, Japanese, other
  71. DepletionofPRPF19regulatescellfatebetweencellular senescence and cell death, 2015/10/10, Without Invitation, Japanese, other
  72. Thenovelmoleculartargetsforanti-cancerdrugtargeting transcription factors, 2015/10/10, Without Invitation, Japanese, other
  73. Identification of novel senescence-associated microRNAs in human fibroblasts, 2015/10/08, Without Invitation, Japanese, other
  74. Liquid Biopsy by using telomere and microRNA, JASIS2015, 2015/09/04, With Invitation, Japanese, other
  75. miR-486 has potential as nucleic acid medicine, 2015/08/27, Without Invitation, Japanese, published
  76. Senescence associated microRNA suppress cell proliferation in pancreatic cancer, 2015/08/27, Without Invitation, Japanese, published
  77. Understanding the mechanisms of the PRPF19 siRNA-mediated anti-tumor effect, 2015/08/27, Without Invitation, Japanese, published
  78. Cell-derived extracellular vesicle regulates cellular senescence, 2015/08/27, Without Invitation, Japanese, published
  79. The analysis of biological significance of extracellular vesicles in replicative senescence, 2015/08/27, Without Invitation, Japanese, published
  80. Role of phage display technology to proteomics, 2015/07/23, Without Invitation, Japanese, other
  81. Stable propagation of human pluripotent stem cells by dual inhibition of PKC and ERK signaling, 2015/05/26, Without Invitation, Japanese, other
  82. A large-scale membrane proteome analysis in scirrhous gastric cancer cell, 2015/05/26, Without Invitation, Japanese, other
  83. High-content screening of senescence-inducible microRNAs, 2015/05/26, Without Invitation, Japanese, other
  84. Analysis of senescence-associated miRNA that suppress pancreatic cancer, 2015/05/26, Without Invitation, Japanese, other
  85. Generation of Werner syndrome-specific iPS cells and challenges towards clinical application, 2015/05/26, Without Invitation, Japanese, other
  86. DNA Damage Response in Human Induced Pluripotent Stem Cells, Akira Shimamoto,Harunobu Kagawa,Hidehiko Kawai,Tetsushi Sakuma,Takashi Yamamoto,Bunsyo Shiotani,Hidetoshi Tahara, ICRR2015, 2015/05/25, Without Invitation, English, other
  87. Senescence-associated EVs act as tumor suppressors in the tumor microenvironment, Hidetoshi Tahara, International Soclety for Extracellular Vesicies 2015, 2015/04/25, Without Invitation, English, experimental

External Funds

Acceptance Results of Competitive Funds

  1. Practical Research for Innovative Cancer Control, 2021/04/01, 2022/03/31
  2. Practical Research for Innovative Cancer Control, 2015/04/01, 2016/03/31
  3. Program for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), 2015/04/01, 2016/03/31
  4. Project focused on developing key technology of discovering and manufacturing drug for next-generation treatment and diagnosis, 2015/04/01, 2016/03/31
  5. 2011
  6. 2011
  7. 2007
  8. KAKENHI, 2014, 2016
  9. KAKENHI, 2014, 2015
  10. KAKENHI, 2014, 2016
  11. KAKENHI, 2013, 2014
  12. KAKENHI, Development of novel cancer specific DDS utilizing circulating microRNA-derived mechanism, 2012, 2013
  13. KAKENHI, Development of novel drug delivery system for micro RNA nucleic biomedicine using exosome from human cultured cells, 2011, 2011
  14. KAKENHI, The CD47-SIRPa signaling blockade accelerates macrophage phagocytic activity against cancer cells, 2011, 2013
  15. KAKENHI, Mechanism of senescence-associated microRNA inhibiting cell growth and metastasis, 2011, 2013
  16. KAKENHI, Mechanism of cancer-selective cell death induced by increased genomic instability and application of the cell death mechanism to cancer therapy, 2008, 2010
  17. KAKENHI, 2008, 2009
  18. KAKENHI, Risk assessment of cancer using telomere G-tail length measurement, 2008, 2009
  19. KAKENHI, Optimal therapeutic approach on ischemic brain insult using bone marrow stromal cells cultured under simulated microgravity, 2008, 2010
  20. KAKENHI, Discovery of the new anti-cancer drug candidates from Okinawan subtropical plants., 2008, 2010
  21. KAKENHI, Mesenchymal stem cells dynamism in microgravity environment., 2007, 2009
  22. KAKENHI, 2007, 2008
  23. KAKENHI, Elucidation of the consequence of telomere single-stand overhang, G-tail, in biology, and application to age-related disease, 2006, 2007
  24. KAKENHI, 2006, 2007
  25. KAKENHI, Identification of compounds that induce or repress telomerase activity, 2003, 2004
  26. KAKENHI, 2003, 2004
  27. KAKENHI, Do telomere regulate in vivo aging?, 2000, 2001
  28. KAKENHI, Cloning and clinical application of telomerase cDNA, 1997, 1998
  29. KAKENHI, 1996, 1996
  30. KAKENHI, 1995, 1995
  31. KAKENHI, 1995, 1995
  32. KAKENHI, cDNA cloning of cellular aging and cellular senescence, 1995, 1996
  33. Health and Labour Sciences Research Grants, 2014/05/01, 2015/03/31
  34. KAKENHI, 2010, 2014
  35. Practical Research for Innovative Cancer Control , 2016/04/01, 2017/03/31
  36. Practical Research for Innovative Cancer Control , 2017/04/01, 2018/03/31
  37. Translational Research Network Program, 2017/07/01, 2018/03/31
  38. Project focused on developing key technology of discovering and manufacturing drug for next-generation treatment and diagnosis , 2017/04/01, 2018/03/31
  39. Practical Research for Innovative Cancer Control , 2018/04/01, 2019/03/31
  40. Translational Research Network Program, 2018/04/01, 2019/03/31
  41. Project focused on developing key technology of discovering and manufacturing drug for next-generation treatment and diagnosis , 2018/04/01, 2019/03/31
  42. Practical Research for Innovative Cancer Control , 2019/04/01, 2020/03/31
  43. Practical Research for Innovative Cancer Control, 2020/04/01, 2021/03/31

Social Activities

Organizing Academic Conferences, etc.

  1. Japanese Association for RNAi, 2022/, 2022/
  2. Japanese Association for RNAi, 2021/, 2021/
  3. 2012/08
  4. The 7th JARI Annual Meeting, 2015/08, 2015/08
  5. The 8th JARI Annual Meeting, 2016/08, 2016/08
  6. The 9th JARI Annual Meeting, 2017/08, 2017/09
  7. 2018/08, 2018/08
  8. Japanese Association for RNAi, 2019/, 2019/
  9. International Society for Extracellular Vesicles, 2018/, 2018/
  10. International Society for Extracellular Vesicles, ISEV2019 INTERNATIONAL ORGANIZING COMMITTEE Chair, 2019/04, 2019/04

History as Peer Reviews of Academic Papers

  1. 2022, Cancer Science, Editor, 15